Oculis Holding AG (OCS) Other Non Operating Income (2022 - 2025)
Oculis Holding AG (OCS) posted quarterly Other Non Operating Income of -$5.7 million for Q2 2025, down 1836.74% year-over-year from $329247.1 in Q2 2024, and down 228.08% quarter-over-quarter from -$1.7 million in Q1 2025.
Oculis Holding AG (OCS) Other Non Operating Income (2022 - 2025) Analysis & Trends
Oculis Holding AG's Other Non Operating Income history runs 4 years deep, the most recent figure standing at -$5.7 million for Q2 2025.
- In Q2 2025, Other Non Operating Income fell 1836.74% year-over-year to -$5.7 million; the TTM figure through Jun 2025 stood at -$7.8 million (down 110.77% YoY), while the FY2024 annual figure was $1.4 million, up 127.78% from the prior year.
- Other Non Operating Income for Q2 2025 stood at -$5.7 million, down from -$1.7 million in the prior quarter.
- The five-year high for Other Non Operating Income was $3.3 million in Q4 2022, with the low at -$5.7 million in Q2 2025.
- The 4-year median for Other Non Operating Income is -$1.3 million (2022), against an average of -$829491.5.
- The sharpest annual moves came in 2024 and 2025: Other Non Operating Income soared 882.33% in 2024, then plunged 1836.74% in 2025.
- Oculis Holding AG's Other Non Operating Income stood at $3.3 million in 2022, then sank by 174.35% to -$2.5 million in 2023, then jumped by 175.75% to $1.9 million in 2024, then sank by 407.32% to -$5.7 million in 2025.
- Business Quant data shows OCS's Other Non Operating Income at -$5.7 million in Q2 2025, -$1.7 million in Q1 2025, and $1.9 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Oculis Holding AG | 879.09 Mn | 590.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -5.72 Mn |
| Mar 31, 2025 | -1.74 Mn |
| Dec 31, 2024 | 1.86 Mn |
| Sep 30, 2024 | -2.18 Mn |
| Jun 30, 2024 | -295,246.86 |
| Mar 31, 2024 | 2.06 Mn |
| Dec 31, 2023 | -2.46 Mn |
| Sep 30, 2023 | -2.99 Mn |
| Jun 30, 2023 | 453,767.62 |
| Mar 31, 2023 | -262,722.51 |
| Dec 31, 2022 | 3.30 Mn |
| Sep 30, 2022 | -1.35 Mn |
| Jun 30, 2022 | -1.46 Mn |